A Phase 1 interventional study of LY3872386 and Prednisone in Healthy and Atopic Dermatitis, sponsored by Eli Lilly and Company. Terminated at 2 sites in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-10-03.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies in Dermatitis, Atopic by Eli Lilly and Company — 1 open to participants now, 2 under way, 2 of them phase 3. Dermatitis, Atopic · Eli Lilly and Company.
Among the 30 studies in Dermatitis, Atopic by Eli Lilly and Company, this one is the 30th largest by enrollment, is one of 4 that started in 2023, is one of 3 in phase 1, and was the 27th registered.
1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.
Browse Dermatitis, Atopic studies →1 of the 30 studies in Dermatitis, Atopic by Eli Lilly and Company is open now, in 12 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States, Argentina, Australia and 10 more countries
Ages 6 mo–18 yrs
By country, each count listing its studies:
Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 4 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 18 is below the median of 82 across 1,248 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 283 across the 30 interventional studies. Of the 28 that completed or were terminated, 25 (89%) have results posted.
This tab as a report to print or save as PDF → With an account.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 30 studies in Dermatitis, Atopic by Eli Lilly and Company, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to evaluate the safety and tolerability of LY3872386 in healthy participants and participants with atopic dermatitis. The safety of prednisone is also evaluated in healthy participants. Blood tests will be performed to investigate how the body processes the LY3872386 following single and multiple dosing in healthy participants and participants with atopic dermatitis. Blood tests will also be performed to investigate how the body processes the prednisone in healthy participants. The study is conducted in three parts (part A, B and C). The study will last up to approximately 85, 183 and 44 days for parts A, B, and C, respectively.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Part A and C:
Overtly healthy as determined by medical evaluation
Part B:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single doses of LY3872386 (low dose, mid dose, and high dose) administered intravenously (IV) in healthy participants.
Drug: LY3872386
Part B was planned but not initiated as study terminated early due to emerging nonclinical data.
Drug: LY3872386
Part C was planned but not initiated as study terminated early due to emerging nonclinical data.
Drug: Prednisone
Placebo administered IV in healthy participants.
Drug: Placebo
Administered IV.
Administered orally.
Administered IV.
Part A: Number of Participants With One or More Treatment Emergent Adverse Events (TEAEs), Serious Adverse Event(s) (SAEs) and Other Non-serious Adverse Events (AEs) Considered by the Investigator to be Related to Study Drug Administration
A summary of SAEs and other non-serious adverse events (AEs), regardless of causality is located in the Reported Adverse Event module. Drug related TEAEs are any untoward medical occurrences that either occurs postdose or presents prior to dosing yet becomes more severe postdose, and in the opinion of the investigator is possibly related to study drug.
Time frame: Baseline through Day 85
Part B: Number of Participants With One or More TEAEs, SAEs and Other Non-serious AEs Considered by the Investigator to be Related to Study Drug Administration
A summary of SAEs and other non-serious adverse events (AEs), regardless of causality is located in the Reported Adverse Event module. Drug related TEAEs are any untoward medical occurrences that either occurs postdose or presents prior to dosing yet becomes more severe postdose, and in the opinion of the investigator is possibly related to study drug. Zero participants were analyzed in this outcome as study was terminated early.
Time frame: Baseline through Day 183
Part C: Number of Participants With One or More TEAEs, SAEs and Other Non-serious AEs Considered by the Investigator to be Related to Study Drug Administration
A summary of SAEs and other non-serious adverse events (AEs), regardless of causality is located in the Reported Adverse Event module. Drug related TEAEs are any untoward medical occurrences that either occurs postdose or presents prior to dosing yet becomes more severe postdose, and in the opinion of the investigator is possibly related to study drug. Zero participants were analyzed in this outcome as study was terminated early.
Time frame: Baseline through Day 44
Pharmacokinetics (PK): Part A and B: Maximum Observed Concentration (Cmax) of LY3872386
Cmax of LY3872386 is reported.
Time frame: Day 1: predose, end of infusion, 3 hours, 6 hours, and 12 hours postdose, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 11, Day 15, Day 22, Day 29, Day 43, Day 57, Day 71 and Day 85 postdose (Part A)
PK: Part A and B: Area Under the Concentration Versus Time Curve (AUC) of LY3872386
Area Under the Concentration Versus Time Curve from Time Zero to tlast (AUC\[0-tlast\]) and Area Under the Concentration Versus Time Curve from Time Zero to Infinity (AUC\[0-inf\]) of LY3872386 is reported.
Time frame: Day 1: predose, end of infusion, 3 hours, 6 hours, and 12 hours postdose, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 11, Day 15, Day 22, Day 29, Day 43, Day 57, Day 71 and Day 85 postdose (Part A)
PK: Part C: Cmax of Prednisone and Prednisolone
Zero participants were analyzed in this outcome as study was terminated early.
Time frame: Predose up to 12 hours post dose on day 14 and day 30
PK: Part C: AUC of Prednisone and Prednisolone
Zero participants were analyzed in this outcome as study was terminated early.
Time frame: Predose up to 12 hours post dose on day 14 and day 30
| Milestone | Part A: Low Dose LY3872386 | Part A: Mid-dose LY3872386 | Part A: High Dose LY3872386 | Part A: Placebo |
|---|---|---|---|---|
| Started | 6 | 6 | 1 | 5 |
| Received at least one dose of study drug | 6 | 6 | 1 | 5 |
| Completed | 6 | 6 | 1 | 5 |
| Not completed | 0 | 0 | 0 | 0 |
A summary of SAEs and other non-serious adverse events (AEs), regardless of causality is located in the Reported Adverse Event module. Drug related TEAEs are any untoward medical occurrences that either occurs postdose or presents prior to dosing yet becomes more severe postdose, and in the opinion of the investigator is possibly related to study drug.
| participants | Part A: Low Dose LY3872386 | Part A: Mid-dose LY3872386 | Part A: High Dose LY3872386 | Part A: Placebo IV |
|---|---|---|---|---|
| TEAEs | 0 | 2 | 0 | 0 |
| SAEs | 0 | 0 | 0 | 0 |
| AEs | 0 | 2 | 0 | 0 |
A summary of SAEs and other non-serious adverse events (AEs), regardless of causality is located in the Reported Adverse Event module. Drug related TEAEs are any untoward medical occurrences that either occurs postdose or presents prior to dosing yet becomes more severe postdose, and in the opinion of the investigator is possibly related to study drug. Zero participants were analyzed in this outcome as study was terminated early.
No measurements were reported for this outcome.
A summary of SAEs and other non-serious adverse events (AEs), regardless of causality is located in the Reported Adverse Event module. Drug related TEAEs are any untoward medical occurrences that either occurs postdose or presents prior to dosing yet becomes more severe postdose, and in the opinion of the investigator is possibly related to study drug. Zero participants were analyzed in this outcome as study was terminated early.
No measurements were reported for this outcome.
Cmax of LY3872386 is reported.
| micrograms per milliliter (µg/mL) | Part A: Low Dose LY3872386 | Part A: Mid-dose LY3872386 | Part A: High Dose LY3872386 | Part B: LY3872386 |
|---|---|---|---|---|
| Pharmacokinetics (PK): Part A and B: Maximum Observed Concentration (Cmax) of LY3872386 | 2.54 ± 16.9 | 7.89 ± 16.3 | NA ± NA | — |
Area Under the Concentration Versus Time Curve from Time Zero to tlast (AUC\[0-tlast\]) and Area Under the Concentration Versus Time Curve from Time Zero to Infinity (AUC\[0-inf\]) of LY3872386 is reported.
| microgram*hour per milliliter(µg*hr/mL) | Part A: Low Dose LY3872386 | Part A: Mid-dose LY3872386 | Part A: High Dose LY3872386 | Part B: LY3872386 |
|---|---|---|---|---|
| AUC(0-tlast) of LY3872386 | 55.7 ± 15.6 | 328 ± 19.7 | NA ± NA | — |
| AUC(0-∞) of LY3872386 | 65.8 ± 18.6 | 337 ± 20.3 | NA ± NA | — |
Zero participants were analyzed in this outcome as study was terminated early.
No measurements were reported for this outcome.
Zero participants were analyzed in this outcome as study was terminated early.
No measurements were reported for this outcome.
Collected over Baseline up to Day 85. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A: Low Dose LY3872386 | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| Part A: Mid-dose LY3872386 | 0/6 (0%) | 0/6 (0%) | 3/6 (50%) |
| Part A: High Dose LY3872386 | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) |
| Part A: Placebo | 0/5 (0%) | 0/5 (0%) | 0/5 (0%) |
| Event | Part A: Low Dose LY3872386 | Part A: Mid-dose LY3872386 | Part A: High Dose LY3872386 | Part A: Placebo |
|---|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 0/6 | 2/6 | 0/1 | 0/5 |
| Conjunctival haemorrhageEye disorders | 0/6 | 1/6 | 0/1 | 0/5 |
| KeratitisEye disorders | 1/6 | 0/6 | 0/1 | 0/5 |
| Injection site erythemaGeneral disorders | 0/6 | 1/6 | 0/1 | 0/5 |
| HeadacheNervous system disorders | 1/6 | 1/6 | 0/1 | 0/5 |
| Menstruation irregularReproductive system and breast disorders | 0/6 | 1/6 | 0/1 | 0/5 |
All randomized participants.
| Age, Categorical(Participants) | Part A: Low Dose LY3872386 | Part A: Mid-dose LY3872386 | Part A: High Dose LY3872386 | Part A: Placebo | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 6 | 6 | 1 | 5 | 18 |
| >=65 years | 0 | 0 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Part A: Low Dose LY3872386 | Part A: Mid-dose LY3872386 | Part A: High Dose LY3872386 | Part A: Placebo | Total |
|---|---|---|---|---|---|
| Female | 2 | 3 | 0 | 2 | 7 |
| Male | 4 | 3 | 1 | 3 | 11 |
| Ethnicity (NIH/OMB)(Participants) | Part A: Low Dose LY3872386 | Part A: Mid-dose LY3872386 | Part A: High Dose LY3872386 | Part A: Placebo | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 2 | 1 | 1 | 5 |
| Not Hispanic or Latino | 5 | 4 | 0 | 4 | 13 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Part A: Low Dose LY3872386 | Part A: Mid-dose LY3872386 | Part A: High Dose LY3872386 | Part A: Placebo | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 0 | 0 | 1 |
| Asian | 0 | 1 | 0 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 3 | 0 | 0 | 0 | 3 |
| White | 2 | 4 | 1 | 5 | 12 |
| More than one race | 1 | 0 | 0 | 0 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Part A: Low Dose LY3872386 | Part A: Mid-dose LY3872386 | Part A: High Dose LY3872386 | Part A: Placebo | Total |
|---|---|---|---|---|---|
| United States | 6 | 6 | 1 | 5 | 18 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Nov 2023 to primary completion in Apr 2024, 5 months.
Results were first posted in Oct 2025, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Prednisone